European Union - Lithuanian - EMA (European Medicines Agency)

laboratoire hra pharma - ulipristalas - kontracepcija, postcoital - lytiniai hormonai ir moduliatoriai lytinių organų sistema, , skubios pagalbos kontraceptikai. - neatidėliotinos kontracepcijos priemonės per 120 valandų (penkias dienas) nuo neapsaugoto lytinio akto ar kontracepcijos nepakankamumo.

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva pharma b.v. - kvetiapinas - plėvele dengtos tabletės - 300 mg; 200 mg; 25 mg - quetiapine

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva pharma b.v. - atorvastatinas - plėvele dengtos tabletės - 80 mg; 40 mg; 20 mg; 10 mg - atorvastatin

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva pharma b.v. - kvinaprilis - plėvele dengtos tabletės - 20 mg; 10 mg; 40 mg - quinapril

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva pharma b.v. - sertralinas - plėvele dengtos tabletės - 50 mg - sertraline

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva pharma b.v. - amlodipinas - tabletės - 10 mg; 5 mg - amlodipine

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva pharma b.v. - finasteridas - plėvele dengtos tabletės - 5 mg - finasteride

Lithuania - Lithuanian - SMCA (Valstybinė vaistų kontrolės tarnyba)

colgate-palmolive (poland) sp. z o.o., wybrzeze gdynskie 6d, pl-01531 warszawa (lenkija). - didecildimetilamonio chloridas - veikliosios medžiagos cas nr.: 7173-51-5, eb nr.: 230-525-2, veikliosios medžiagos pavadinimas: didecildimetilamonio chloridas, koncentracija: 0.65% , veiklioji - maisto ir pašarų sritis

European Union - Lithuanian - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - krūties navikai - antinavikiniai vaistai - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

European Union - Lithuanian - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antinavikiniai vaistai - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.